These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 1380906)
1. Development of effective drug combinations for the inhibition of multiply resistant mycobacteria, especially of the Mycobacterium avium complex. Seydel JK; Schaper KJ; Rüsch-Gerdes S Chemotherapy; 1992; 38(3):159-68. PubMed ID: 1380906 [TBL] [Abstract][Full Text] [Related]
2. [A new, highly synergistic drug combination for the treatment of infections with multiresistant mycobacteria, especially the mycobacterium avium complex]. Seydel JK; Schaper KJ Immun Infekt; 1992 Apr; 20(2):46-9. PubMed ID: 1377169 [TBL] [Abstract][Full Text] [Related]
3. In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex. Stauffer F; Dörtbudak O; Lahonik E Infection; 1991; 19(5):343-5. PubMed ID: 1839300 [TBL] [Abstract][Full Text] [Related]
4. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium. Hoffner SE; Svenson SB; Källenius G Eur J Clin Microbiol; 1987 Oct; 6(5):530-5. PubMed ID: 3436314 [TBL] [Abstract][Full Text] [Related]
5. In vitro synergistic activity of ethambutol, isoniazid, kanamycin, rifampin, and streptomycin against Mycobacterium avium-intracellulare complex. Zimmer BL; DeYoung DR; Roberts GD Antimicrob Agents Chemother; 1982 Jul; 22(1):148-50. PubMed ID: 7125626 [TBL] [Abstract][Full Text] [Related]
6. Synergistic antimycobacterial activity between ethambutol and the beta-lactam drug cefepime. Abate G; Hoffner SE Diagn Microbiol Infect Dis; 1997 Jul; 28(3):119-22. PubMed ID: 9294701 [TBL] [Abstract][Full Text] [Related]
7. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Rastogi N; Goh KS; Bryskier A Antimicrob Agents Chemother; 1994 Jun; 38(6):1433-8. PubMed ID: 8092850 [TBL] [Abstract][Full Text] [Related]
8. In vitro susceptibility of Mycobacterium avium complex to the new fluoroquinolone sparfloxacin (CI-978; AT-4140) and comparison with ciprofloxacin. Yajko DM; Sanders CA; Nassos PS; Hadley WK Antimicrob Agents Chemother; 1990 Dec; 34(12):2442-4. PubMed ID: 2088204 [TBL] [Abstract][Full Text] [Related]
9. [Determination of resistance of Mycobacterium tuberculosis against isonicotinic acid hydrazide, streptomycin, para-aminosalicylic acid, ethionamide, ethambutol and rifampicin using the 32 P incorporation test]. Reutgen H Acta Biol Med Ger; 1973; 30(3):309-16. PubMed ID: 4202698 [No Abstract] [Full Text] [Related]
10. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969 [TBL] [Abstract][Full Text] [Related]
11. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Banks J; Jenkins PA Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264 [TBL] [Abstract][Full Text] [Related]
12. Anti-Mycobacterium avium complex activity of clarithromycin, rifampin, rifabutin, and ethambutol in combination with adenosine 5'-triphosphate. Tatano Y; Yamabe S; Sano C; Tomioka H Diagn Microbiol Infect Dis; 2017 Jul; 88(3):241-246. PubMed ID: 28511780 [TBL] [Abstract][Full Text] [Related]
13. [Sensitivity to rifampicin and ethambutol of mycobacteria resistant to isoniazid or streptomycin]. Golychevskaja VI G Ital Chemioter; 1972; 19(2):20-2. PubMed ID: 4199029 [No Abstract] [Full Text] [Related]
14. Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. Heifets LB; Iseman MD; Lindholm-Levy PJ Am Rev Respir Dis; 1988 Mar; 137(3):711-5. PubMed ID: 2830814 [TBL] [Abstract][Full Text] [Related]
15. Drug resistance in tuberculosis in Delhi: a 2 year profile (2001--2002). Negi SS; Gupta S; Lal S J Commun Dis; 2003 Jun; 35(2):74-81. PubMed ID: 15562952 [TBL] [Abstract][Full Text] [Related]
16. Primary resistance to anti-tuberculosis drugs in Addis Ababa, Ethiopia. Demissie M; Gebeyehu M; Berhane Y Int J Tuberc Lung Dis; 1997 Feb; 1(1):64-7. PubMed ID: 9441061 [TBL] [Abstract][Full Text] [Related]
17. [In vitro susceptibilities of Mycobacterium avium and Mycobacterium intracellulare to various drugs]. Tomioka H; Sato K; Saito H Kekkaku; 1991 Jul; 66(7):489-92. PubMed ID: 1890791 [TBL] [Abstract][Full Text] [Related]
18. Paradoxical effect of Tween 80 between the susceptibility to rifampicin and streptomycin and the susceptibility to ethambutol and sulfadimethoxine in the Mycobacterium avium-Mycobacterium intracellulare complex. Yamori S; Tsukamura M Microbiol Immunol; 1991; 35(10):921-6. PubMed ID: 1779893 [TBL] [Abstract][Full Text] [Related]
19. [Synergistic effects of davercin, rifampicin, ethambutol and isonicotinic acid hydrazide on selected standard strains of Mycobacterium in the in-vitro and in-vivo experiments]. Janowiec M; Andrzejczyk Z; Szwedowicz I Pneumonol Pol; 1988 Jun; 56(6):278-82. PubMed ID: 3226945 [No Abstract] [Full Text] [Related]
20. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex. Hoffner SE; Kratz M; Olsson-Liljequist B; Svenson SB; Källenius G J Antimicrob Chemother; 1989 Sep; 24(3):317-24. PubMed ID: 2808189 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]